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S U M M A R Y
The aim of this paper is to deliver a perspective on future Nobel prizes by reviewing the features of Nobel
prizes awarded in the infectious diseases-related (IDR) ﬁeld over the last 115 years. Thirty-three out of
106 Nobel prizes (31%) in Physiology or Medicine have been awarded for IDR topics. Out of 58 Nobel
laureates for IDR topics, two have been female; 67% have been medical doctors. The median age of Nobel
laureates in Physiology or Medicine was found to be lower than the median age of laureates in Literature
(p < 0.001). Since the Second World War, US-afﬁliated scientists have dominated the Nobel prizes (53%);
however before 1945, German scientists did so (p = 0.005). The new antimicrobials received Nobel prizes
until 1960; however no treatment study was awarded the Prize until the discovery of artemisinin and
ivermectin, for which the Nobel Prize was awarded in 2015. Collaborative works have increasingly been
appreciated. In the future, more female laureates would be expected in the IDR ﬁeld. Medical graduates
and scientists involved in multi-institutional and multidisciplinary collaborative efforts seem to have an
advantage.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Appreciation of the scientiﬁc achievements made in medicine
and infectious diseases is not easy. The most reliable measure of
scientiﬁc endeavours may be the contribution made to the world’s
health. This would necessitate years of observation to detect the
value of the contribution. Tracking and evaluating the Nobel prizes
awarded and the Nobel laureates could be a means of acknowl-
edging scientiﬁc developments. Despite some criticisms, the Nobel
Prize is considered by many to be one of the most prestigious
awards and a worldwide appreciation of speciﬁc scientiﬁc
contributions.
The Nobel prizes have been awarded since 1895, based on the
will of the Swedish inventor Alfred Nobel. Nobel prizes are
currently awarded in the ﬁelds of Physics, Chemistry, Economic
Sciences, Literature, Peace, and Physiology or Medicine. The ﬁrst
prize in the ﬁeld of Physiology or Medicine was bestowed on Emil
Adolf von Behring for his work on serum therapy against
diphtheria; this Prize was awarded on December 10, 1901, on* Corresponding author.
E-mail address: oergonul@ku.edu.tr (O. Ergonul).
http://dx.doi.org/10.1016/j.ijid.2016.02.022
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).the ﬁfth anniversary of Alfred Nobel’s death.1 The latest Nobel Prize
in Physiology or Medicine, announced on October 5, 2015, was
presented to two studies related to the infectious diseases ﬁeld,
which placed a spotlight on this ﬁeld of medicine.
As of 2015, 106 Nobel prizes in Physiology or Medicine have
been awarded to 210 laureates, with 33 of these prizes related to
the realm of infectious diseases, clinical microbiology, and
immunology. This review focuses on the Nobel laureates and
their contributions to the ﬁelds of physiology or medicine and
infectious diseases. By tracking the Nobel laureates, it was aimed to
detail the developments achieved in the infectious diseases-
related (IDR) ﬁelds over the last 115 years in order to infer
information for future scientists.
2. Methods
Data on the laureates, including age, sex, country of birth,
afﬁliation, prize motivation, and whether the prize was shared or
not, were retrieved from the ofﬁcial website of the Nobel Prize
(http://www.nobelprize.org). The Chi-square test for categorical
data and the t-test for continuous data were used to analyse the
data; statistical signiﬁcance was set at p < 0.05. STATA 13 (Stata
Corp, College Station, TX, USA) was used for the statistical analysis.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Austra lia
China
USA
Japan
Switzerlan d
Tunis
Austria
Denm ark
Belg ium
German y
United
Kingdom
France
Figure 1. Percentile distribution of the countries of the Nobel laureates’ afﬁliated
institutions before and after 1945.
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The proportion of IDR awards for the Nobel Prize in Medicine or
Physiology is 31%. The demographic features of the Nobel laureates
with IDR awards and those of the laureates of the separate
Physiology or Medicine, Chemistry, Physics, Literature, Economic
Sciences, and Peace prizes are presented in Table 1.
Scientists from the USA, UK, and France have been the most
frequently represented. France has had a larger share of the Nobel
prizes in IDR ﬁelds than in Literature, which may be attributed to
the Pasteur Institute being awarded a prize ﬁve times. Two
additional points can be made from these data, including the
substantial discrepancy between the sexes of the Nobel laureates
in the areas of Physiology or Medicine and Literature (p = 0.099).
The discrepancy in sex is most prominent in the IDR Physiology or
Medicine prizes, with only two female laureates out of 58:
Franc¸oise Barre´-Sinoussi2 and Youyou Tu. Laureates with a medical
degree have represented 67% of the laureates in the IDR ﬁeld and
58% of the awardees in Physiology or Medicine. The mean age of
Nobel laureates in IDR ﬁelds does not differ signiﬁcantly from that
of the Medicine or Physiology Nobel laureates. However, the
median age of all Nobel laureates in Physiology or Medicine is
lower than the median age of laureates in Literature (p < 0.001).
Peyton Rous has been the oldest Nobel laureate to receive the
Nobel Prize in the IDR ﬁeld; this was awarded for his work on
tumour-inducing viruses in 1966 at the age of 87 years.3 In the IDR
ﬁeld, Joshua Lederberg won the Nobel Prize at the age of 33 years
for his work on the genetic material of bacteria; he was 1 year older
than Frederick G. Banting, who was awarded the prize in
Physiology or Medicine at 32 years old and who is therefore the
youngest Nobel Laureate in Physiology or Medicine. Another
interesting fact concerns Ralph Steinman, whose work on dendritic
cells was acknowledged with a Nobel Prize. Ralph Steinman was
announced to be the 2011 Nobel Prize Laureate in Physiology or
Medicine 3 days after his death; the Nobel Assembly at Karolinska
Institutet was unaware of this fact at the time of the announce-
ment. Although a decision made in 1974 precluded the awarding of
posthumous Nobel prizes, the Board of the Nobel Foundation
accepted Ralph Steinman as a Nobel Laureate.
The number of Nobel laureates in the IDR ﬁeld peaked between
1976 and 1990. Since the Second World War (1945), the leading
afﬁliation has been the USA. The number of Nobel laureates
afﬁliated with institutions in Germany declined abruptly after
1945 (Figure 1). Scientists afﬁliated with institutions in the USA
have dominated the Nobel prizes in the IDR ﬁeld, with 23 ofTable 1
Demographic characteristics of Nobel laureates in the infectious diseases-related ﬁeld a
Economic Studies, and Peace)
Infectious diseases-
related ﬁeld
(N = 58), n (%)
Nobel Prize in
Physiology
or Medicine
(N = 210), n (%)
Nobel Prize in
Chemistry
(N = 171a), n (%)
Female sex 2 (3%) 12 (5%) 4 (2%) 
Mean age, years
(min–max)
58 (33–87) 58 (32–87) 58 (35–85) 
Medical doctor 39 (67%) 121 (58%) 13 (8%) 
Afﬁliationsd
USA 23 (40%) 106 (50%) 79 (42%) 
France 10 (17%) 10 (5%) 10 (5%) 
UK 7 (12%) 31 (15%) 28 (15%) 
Germany 5 (9%) 15 (7%) 27 (14%) 
Switzerland 4 (7%) 8 (4%) 6 (3%) 
a 172 prizes have been awarded in the ﬁeld of Chemistry; however since Frederick 
b 201 prizes have been awarded in the ﬁeld of Physics; however since John Bardeen
c 129 Nobel Peace Prizes have been awarded, 103 to individuals and 26 to organiza
d For the country of afﬁliation, the total number is higher than the number of laureates
the prize.43 laureates (53%) after 1945; however, scientists afﬁliated with
US institutions did not win a single prize before 1945 (p < 0.001).
The number of laureates afﬁliated with institutions in Germany
was also found to be statistically signiﬁcant (p = 0.005), with four
laureates before 1945 and only one after 1945; however the
number of laureates from the UK has been stable, with four
laureates before 1945 and three after. With the announcement of
the Nobel Prize in Physiology or Medicine in 2015, scientists in the
IDR ﬁeld afﬁliated with institutions in Japan and China have been
recognized for the ﬁrst time in Nobel Prize history: Satoshi O¯mura
and Youyou Tu.
For analysis, prizes in the IDR ﬁeld were grouped by topic
(Table 2 and Figure 2). Prizes for treatment-related studiesnd for the individual prizes (Medicine or Physiology, Chemistry, Physics, Literature,
Nobel Prize in
Physics
(N = 200b), n (%)
Nobel Prize in
Literature
(N = 111), n (%)
Nobel Prize in
Economic
Sciences
(N = 76), n (%)
Nobel Peace
Prize
(N = 103c), n (%)
2 (1%) 12 (11%) 1 (1%) 16 (16%)
55 (25–88) 65 (42–88) 67 (51–90) 61 (17–87)
- - - -
101 (46%) 11 (10%) 62 (78%) 21 (20%)
16 (7%) 16 (14%) 2 (3%) 9 (9%)
26 (12%) 11 (10%) 6 (8%) 11 (11%)
15 (7%) 6 (5%) 0 (0%) 3 (3%)
8 (4%) 2 (2%) 0 (0%) 3 (3%)
Sanger received the award twice, there have been 171 laureates in total.
 received the award twice, there have been 200 laureates in total.
tions. For demographic information, the organizations have been disregarded.
, since some were afﬁliated with more than one institution at the time they received
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of antibiotics; however, a Nobel Prize was not awarded for the
treatment of infections until 2015.4,5 Microbiology, on the other
hand, has been the most frequently awarded category throughout
the whole century (approximately two of every ﬁve IDR Nobel
prizes), followed by immunology, which remains a very active
ﬁeld, with the latest contributions made by Ralph Steinman, JulesTable 2
List of Nobel laureates in infectious diseases-related ﬁelds
Field Year Name Prize motiva
Epidemiology 1902 Ronald Ross Work on mal
foundation fo
1928 Charles Jules Henri Nicolle Work on typ
1976 Baruch S. Blumberg
D. Carleton Gajdusek
Discoveries c
Virology 1951 Max Theiler Discoveries c
1954 John Franklin Enders
Thomas Huckle Weller
Frederick Chapman Robbins
Discovery of 
1969 Max Delbru¨ck
Alfred D. Hershey
Salvador E. Luria
Discoveries c
1989 J. Michael Bishop
Harold E. Varmus
Discovery of 
2008 Harald zur Hausen Discovery of 
Bacteriology 1958 Joshua Lederberg Discoveries c
bacteria
1965 Franc¸ois Jacob
Andre´ Lwoff
Jacques Monod
Discoveries c
2005 Barry J. Marshall
J. Robin Warren
Discovery of 
Parasitology 1926 Johannes Andreas Grib Fibiger Discovery of 
New agent (prion) 1997 Stanley B. Prusiner Discovery of 
New agent (virus) 1966 Peyton Rous Discovery of 
2008 Franc¸oise Barre´-Sinoussi
Luc Montagnier
Discovery of 
New agent (bacteria) 1905 Robert Koch Investigation
New agent (parasite) 1907 Charles Louis Alphonse Laveran Work on the
Immunology 1901 Emil Adolf von Behring Work on seru
new road in t
victorious we
1908 Ilya Ilyich Mechnikov
Paul Ehrlich
Work on imm
1913 Charles Robert Richet Work on ana
1919 Jules Bordet Discoveries r
1960 Sir Frank Macfarlane Burnet
Peter Brian Medawar
Discovery of 
1972 Gerald M. Edelman
Rodney R. Porter
Discoveries c
1980 Jean Dausset
Baruj Benacerraf
George D. Snell
Discoveries c
immunologic
1984 Niels K. Jerne
Georges J.F. Ko¨hler
Ce´sar Milstein
Theories conc
discovery of 
1987 Susumu Tonegawa Discovery of 
1996 Peter C. Doherty
Rolf M. Zinkernagel
Discoveries c
2011 Bruce A. Beutler
Jules A. Hoffmann
Discoveries c
2011 Ralph M. Steinman Discovery of 
Treatment 1927 Julius Wagner-Jauregg Discovery of 
paralytica
1948 Paul Hermann Mu¨ller Discovery of 
2015 William C. Campbell
Satoshi O¯mura
Discovery of 
2015 Youyou Tu Discovery of 
Treatment
(new antibiotic)
1939 Gerhard Domagk Discovery of 
1945 Sir Alexander Fleming
Ernst Boris Chain
Sir Howard Walter Florey
Discovery of 
1952 Selman Abraham Waksman Discovery of Alphonse Hoffmann, and Bruce Alan Beutler in 2011. With the
recent development of artemisinin and ivermectin against malaria
and roundworm infections, respectively, two scientists working on
the treatment of parasitic infections received the Nobel Prize in
Physiology or Medicine in 2015.6 Although with the exception of
prizes awarded for the discovery of new agents, only one
microbiology study was awarded during the ﬁrst half of the 20thtion
aria, by which he has shown how it enters the organism and thereby has laid the
r successful research on this disease and methods of combating it
hus
oncerning new mechanisms for the origin and dissemination of infectious diseases
oncerning yellow fever and how to combat it
the ability of poliomyelitis viruses to grow in cultures of various types of tissue
oncerning the replication mechanism and the genetic structure of viruses
the cellular origin of retroviral oncogenes
human papillomaviruses causing cervical cancer
oncerning genetic recombination and the organization of the genetic material of
oncerning genetic control of enzyme and virus synthesis
the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease
the Spiroptera carcinoma
prions—a new biological principle of infection
tumour-inducing viruses
human immunodeﬁciency virus
s and discoveries in relation to tuberculosis
 role played by protozoa in causing diseases
m therapy, especially its application against diphtheria, by which he has opened a
he domain of medical science and thereby placed in the hands of the physician a
apon against illness and deaths
unity
phylaxis
elating to immunity
acquired immunological tolerance
oncerning the chemical structure of antibodies
oncerning genetically determined structures on the cell surface that regulate
al reactions
erning the speciﬁcity in development and control of the immune system and the
the principle for production of monoclonal antibodies
the genetic principle for generation of antibody diversity
oncerning the speciﬁcity of the cell-mediated immune defence
oncerning the activation of innate immunity
the dendritic cell and its role in adaptive immunity
the therapeutic value of malaria inoculation in the treatment of dementia
the high efﬁciency of DDT as a contact poison against several arthropods
a therapy against roundworm infections
a therapy against malaria
the antibacterial effects of prontosil
penicillin and its curative effect in various infectious diseases
streptomycin, the ﬁrst antibiotic effective against tuberculosis
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Figure 2. Overview of the infectious diseases-related Nobel prizes with respect to
their categories.
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studies in this ﬁeld increased constantly in the following years,
constituting 39% of all IDR Nobel prizes.
After analysis of the data, 10 items related to future
perspectives were identiﬁed.
(1) Considering the fact that both of the female Nobel laureates
were awarded the Nobel Prize within the last decade, it is
expected that there will be more female Nobel laureates in the
future. The proportion of female Nobel laureates in IDR ﬁelds
may increase.
(2) Sixty-seven percent of these Nobel laureates have had an MD
degree, and the road to the Nobel Prize is always open for
those who choose to attend medical school.
(3) The discovery of new microorganisms responsible for
prevalent diseases could always result in an award.
(4) The discovery of novel mechanisms of pathogenesis in
emerging viral infections that could lead to new treatment
options for previously unknown pathways and preventive
measures could attract a Nobel Prize.
(5) A surprising infectious aetiology for a health problem with
high morbidity, such as dementia, schizophrenia, obesity,
inﬂammatory bowel diseases, and diseases known to be
autoimmune in origin could strongly attract a Nobel Prize.
(6) An entirely new antimicrobial molecule that could be a
response to the global threat of antibiotic resistance could
gain attention.
(7) The ﬁrst Nobel Prize was given to a study in immunology, and
this ﬁeld is still important. Besides the effective immunization
against prevalent infectious diseases, vaccine discoveries
against non-communicable diseases such as cancer and
obesity would also be attractive.
(8) More than 100 years after the study of Ronald Ross on
infectious disease epidemiology, a highly predictive epidemi-
ological tool that includes all of the potential confoundingparameters and directly applicable to daily life would be a
useful solution that could increase the capacity to combat
outbreaks and could attract a Nobel Prize.
(9) Individual Nobel prizes in the IDR ﬁeld were more common in
the ﬁrst half of the 1900s; however collaborative works from
different disciplines have been seen increasingly throughout
the years, becoming more common in the second half of the
1900s (p = 0.002). The authors’ think that collaborative
studies from different disciplines, and those that build a
bridge between the basic and clinical sciences, will have a
greater chance of being awarded a Nobel Prize.
(10) In light of the latest discoveries of new species of micro-
organisms, studies changing our understanding of their
evolution, which could change the taxonomy of microorgan-
isms, may be the focus of a future Nobel Prize.
Finally, these predictions have some conﬁdence limits; within
the nature of discoveries, the Nobel Prize could always surprise us
with an unpredictable discovery!
4. Conclusions
The 115-year history of Nobel prizes for Physiology or Medicine,
mainly in the IDR area, was reviewed. As has started to be seen for
the Medicine or Physiology Prize, it is expected that more female
laureates will be awarded prizes in the IDR ﬁeld as well. Despite the
higher proportion of PhD degrees than MD degrees, the number of
laureates holding an MD degree was strikingly high. The mean age
of the IDR laureates was found not to differ from that of all
Physiology or Medicine laureates; however, both groups of
laureates received their prizes at a signiﬁcantly lower age than
Literature laureates. By focusing on certain countries, an effect of
the Second World War on the country distribution of prizes was
demonstrated. Immunology studies have continued to garner a
high level of interest; prizes for works on new agents are gaining
increasing attention. The global trends in scientiﬁc studies have
increased collaborative efforts, including joint works involving
different disciplines.
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